The U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to TI-168, a T-cell therapy developed by Baudax Bio to treat people with hemophilia A and an inhibitor. ODD, which is granted by the FDA’s Office of Orphan…
Some compelling results from the ‘Hemophilia Life Stages and Changes Global Survey’ were recently announced in a new press release. The survey was conducted by a global market research firm The Harris Poll and sponsored by Sanofi.
More than 2,700…
About coreHEM-MHODeveloped through an initiative co-led by NBDF, coreHEM Mental Health Outlook questionnaire (coreHEM-MHO) is a patient-reported outcome measurement (PROM) instrument that assesses mental health outlook (including psychological…
The THSNA Summit is a collaboration of the 13 leading non-profit organizations (including NBDF) in the fields of Thrombosis and Hemostasis. The Summit provides a focused forum for over 1,000 attendees with an interest in bleeding and clotting…
Recently, Pathway to Cures (P2C) -- NBDF's venture philanthropy fund -- announced exciting updates. Click below to read important press releases.
PATHWAY TO CURES NAMES FIRST MEMBERS TO SCIENTIFIC ADVISORY GROUP
PATHWAY TO…
Presenting the National Research Blueprint for Public Comment
Speaker: Maria Santaella, Vice President of Research Strategy, NBDF & Dr. Michael Recht, Chief Medical and Scientific Officer, NBDF
The National…
Beyond the Guidelines: Challenging Scenarios of Diagnosing von Willebrand Disease
Speaker: Yazan Abou-Ismail, MD, Assistant Professor of Hematology at University of Utah & Jasmine Pauldurai, Education Specialist, NBDF…
Untold Journeys: A Glimpse into Ultra-Rare Bleeding DisordersModerator: Michael DeGrandpre, Community AdvocatePanelist 1: Paxton Mills, Person with Platelet Storage Pool DeficiencyPanelist 2: Troy Longman, Person with…